PriceTargets.com logo

Inhibikase Therapeutics - IKT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $27.00
  • Forecasted Upside: 1,185.71%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.10 As of 04/18/2024 01:00 AM ET
▼ -0.03 (-1.41%)

This chart shows the closing price for IKT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inhibikase Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IKT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IKT

Analyst Price Target is $27.00
▲ +1,185.71% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Inhibikase Therapeutics in the last 3 months. The average price target is $27.00, with a high forecast of $27.00 and a low forecast of $27.00. The average price target represents a 1,185.71% upside from the last price of $2.10.

This chart shows the closing price for IKT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Inhibikase Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00Low
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$27.00Low
4/18/2023HC WainwrightReiterated RatingBuyLow
11/16/2022JonestradingDowngradeBuy ➝ HoldLow
7/15/2021JonestradingInitiated CoverageBuy$72.00High
4/26/2021ThinkEquityInitiated CoverageBuyHigh
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
2/19/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Inhibikase Therapeutics logo
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Read More

Today's Range

Now: $2.10
Low: $2.04
High: $2.15

50 Day Range

MA: $2.24
Low: $1.93
High: $2.68

52 Week Range

Now: $2.10
Low: $0.79
High: $4.35

Volume

27,598 shs

Average Volume

35,700 shs

Market Capitalization

$13.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Inhibikase Therapeutics?

The following Wall Street sell-side analysts have issued reports on Inhibikase Therapeutics in the last year: HC Wainwright.
View the latest analyst ratings for IKT.

What is the current price target for Inhibikase Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Inhibikase Therapeutics in the last year. Their average twelve-month price target is $27.00, suggesting a possible upside of 1,185.7%. HC Wainwright has the highest price target set, predicting IKT will reach $27.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $27.00 for Inhibikase Therapeutics in the next year.
View the latest price targets for IKT.

What is the current consensus analyst rating for Inhibikase Therapeutics?

Inhibikase Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IKT will outperform the market and that investors should add to their positions of Inhibikase Therapeutics.
View the latest ratings for IKT.

What other companies compete with Inhibikase Therapeutics?

Other companies that are similar to Inhibikase Therapeutics include Senti Biosciences, Coeptis Therapeutics, Sorrento Therapeutics, Genetic Technologies and Organovo. Learn More about companies similar to Inhibikase Therapeutics.

How do I contact Inhibikase Therapeutics' investor relations team?

The company's listed phone number is 678-392-3419 and its investor relations email address is [email protected]. The official website for Inhibikase Therapeutics is www.inhibikase.com. Learn More about contacing Inhibikase Therapeutics investor relations.